---
title: "Here's How Much $100 Invested In Amgen 15 Years Ago Would Be Worth Today"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279107370.md"
description: "Amgen (NASDAQ:AMGN) has delivered an average annual return of 13.74% over the past 15 years, outperforming the market by 2.26%. With a current market capitalization of $197.41 billion, a $100 investment in AMGN 15 years ago would now be worth $691.75, highlighting the significant impact of compounded returns on investment growth."
datetime: "2026-03-13T22:17:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279107370.md)
  - [en](https://longbridge.com/en/news/279107370.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279107370.md)
---

# Here's How Much $100 Invested In Amgen 15 Years Ago Would Be Worth Today

Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 2.26% on an annualized basis producing an average annual return of 13.74%. Currently, Amgen has a market capitalization of $197.41 billion.

**Buying $100 In AMGN:** If an investor had bought $100 of AMGN stock 15 years ago, it would be worth **$691.75** today based on a price of $366.21 for AMGN at the time of writing.

### Amgen's Performance Over Last 15 Years

![comp_fig](https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1773440276_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.

_This article was generated by Benzinga's automated content engine and reviewed by an editor._

### Related Stocks

- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)

## Related News & Research

- [Key facts: Amgen tarlatamab approved in China; TEPEZZA SC 77% response](https://longbridge.com/en/news/282383300.md)
- [Amgen's lung cancer drug tarlatamab wins China approval](https://longbridge.com/en/news/282309830.md)
- [PolyPid To Present New Phase 3 SHIELD II Data On D-PLEX100 At ESCMID 2026](https://longbridge.com/en/news/282665678.md)
- [<![CDATA[Pharmaceutical Executive Daily: China Approves Amgen's Tarlatamab for Previously Treated Extensive-Stage Small Cell Lung Cancer]]>](https://longbridge.com/en/news/282383709.md)
- [<![CDATA[Amgen’s Tarlatamab Approved in China ]]>](https://longbridge.com/en/news/282355594.md)